Geniom now at Prognosys and UCSF
Two renowned institutes decided to upgrade their genome analysis facilities by Geniom Technology
Prognosys is the first research site in the US that decided last spring to establish the Geniom microarray platform as genetic analysis tool in their laboratory. Dr. Stefan Matysiak, Vice President & General Manger of febit inc., stated, “Prognosys is a crucial reference site for febit inc. Cooperations and clients like Marc Chee, founder and CEO of Prognosys, are extremely valuable in respect of a market characterized by particular dynamics and a high rate of innovation. We believe that in the near future the Geniom Technology will play an important role within the market of microarray analysis based on its high quality and unique flexibility.”
With the UCSF a very renowned and well equipped institute decided for Geniom to enhance the pool of cutting edge technology at its Center for Advanced Technology (CAT). To get Geniom-supported research up and running as soon as possible, febit sent as a part of its customer service a team of specialists to train the UCSF laboratory team onsite, and optimizes the highly-advanced system to the scientists needs.
febit inc., affiliated company of febit biotech gmbh from Heidelberg (Germany) commenced its operations in August, 2006 in Medford, Massachusetts (USA). During the last several months, febit inc. has built a powerful and competent team for sales, service and customer consulting and established an application lab for potential customers to test the Geniom platform’s ability to produce their specific requirements.
Hummingbird Diagnostics GmbH
Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications (Geno-, SNP- and Pathogentyping, Enzyme-on-Chip, miRNA-Profiling and many more). With the unique Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
„AppliedAI“-Initiative will KI in Deutschland voranbringen
Jedes Jahr ein deutsches Start-up aus dem Umfeld der Künstlichen Intelligenz (KI) in die internationalen Top-100-Listen bringen – so lautet eines der Ziele, das sich die Initiative „AppliedAI“ auf die Fahne geschrieben hat. Unter der Ägide der Bayerischen Staatsregierung und mit Unterstützung der Technischen Universität München kooperieren 26 Forschungseinrichtungen und Konzerne.Weiterlesen